Shots:
- EC approved Exdensur as an add-on maintenance therapy for asthma pts (≥12yrs.) with type 2 inflammation (eosinophilic) & as add-on therapy for inadequately controlled CRSwNP, based on P-III (SWIFT & ANCHOR) trials, respectively
- In SWIFT-1 (n=382) & SWIFT-2 (n=380), Exdensur reduced asthma exacerbations by 58% & 48% over 52wks. (1EP), with pooled data showing a 72% reduction in hospitalizations vs PBO + SoC, & fewer exacerbations resulting in hospital/ER events (1% & 4% vs 8% & 10%)
- ANCHOR-1 (n=271) & ANCHOR-2 (n=257) trials assessed Exdensur vs PBO in CRSwNP pts on intranasal corticosteroids, which showed reduced nasal polyp size at 52wks. & improved nasal obstruction verbal response over Wks. 49-52
Ref: GSK | Image: GSK | Press Release
Related News: NMPA Accepts GSK’s Arexvy Submission to Prevent Lower Respiratory Tract Disease in Adults
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
